Profile data is unavailable for this security.
About the company
Corcept Therapeutics Incorporated is a commercial-stage company, which is engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic and neurological disorders by modulating the effects of the hormone cortisol. The Company operates through the discovery, development and commercialization of the pharmaceutical products segment. The Company has marketed Korlym (mifepristone) in the United States for the treatment of patients suffering from Cushings syndrome. The Company’s portfolio of selective cortisol modulators consists of four series totaling approximately 1,000 compounds. Its portfolio of selective cortisol modulators consists of relacorilant, exicorilant, dazucorilant and miricorilant. Korlyms active ingredient, mifepristone, reduces the binding of excess cortisol to the GR, it can modulate the effects of abnormal levels and release patterns of cortisol without compromising cortisols healthy functions and rhythms.
- Revenue in USD (TTM)523.53m
- Net income in USD118.02m
- Incorporated1998
- Employees352.00
- LocationCorcept Therapeutics Inc149 Commonwealth DrMENLO PARK 94025United StatesUSA
- Phone+1 (650) 688-8803
- Fax+1 (650) 327-3218
- Websitehttps://www.corcept.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Arcellx Inc | 131.66m | -50.54m | 2.78bn | 130.00 | -- | 5.58 | -- | 21.13 | -1.04 | -1.04 | 2.66 | 9.32 | 0.1877 | -- | -- | 1,012,792.00 | -7.21 | -38.82 | -8.96 | -45.41 | -- | -- | -38.39 | -339.38 | -- | -- | 0.0615 | -- | -- | -- | 62.53 | -- | 113.86 | -- |
| PTC Therapeutics, Inc. | 927.56m | -579.22m | 2.79bn | 988.00 | -- | -- | -- | 3.01 | -7.69 | -7.69 | 12.28 | -11.66 | 0.5459 | 2.33 | 4.64 | 938,823.90 | -34.09 | -26.71 | -48.63 | -33.46 | 92.88 | 93.94 | -62.45 | -83.80 | 1.98 | -0.7975 | 1.72 | -- | 34.20 | 28.78 | -12.09 | -- | 32.00 | -- |
| Neogen Corp | 929.24m | 1.57m | 2.85bn | 2.64k | 1,823.86 | 0.9054 | 24.17 | 3.07 | 0.0072 | 0.0072 | 4.29 | 14.52 | 0.2044 | 2.79 | 5.81 | 351,984.10 | 0.0345 | 3.44 | 0.0355 | 3.62 | 50.97 | 47.25 | 0.1685 | 7.77 | 2.66 | 1.31 | 0.2205 | 0.00 | 56.01 | 15.63 | -147.34 | -- | 25.71 | -- |
| Arrowhead Pharmaceuticals Inc | 35.47m | -470.79m | 2.85bn | 525.00 | -- | 5.89 | -- | 80.35 | -4.24 | -4.24 | 0.3189 | 3.90 | 0.0384 | -- | -- | 67,567.62 | -51.72 | -20.02 | -57.39 | -24.65 | -- | -- | -1,346.13 | -61.79 | -- | -80.00 | 0.00 | -- | -1.03 | 71.68 | -16.59 | -- | 162.38 | -- |
| Xenon Pharmaceuticals Inc | 0.00 | -188.60m | 2.87bn | 251.00 | -- | 3.24 | -- | -- | -2.71 | -2.71 | 0.00 | 11.76 | 0.00 | -- | -- | 0.00 | -23.02 | -20.71 | -23.66 | -21.81 | -- | -- | -- | -683.58 | -- | -- | 0.00 | -- | -100.00 | -- | -45.99 | -- | 61.77 | -- |
| Amicus Therapeutics, Inc. | 423.49m | -147.07m | 2.90bn | 517.00 | -- | 22.21 | -- | 6.85 | -0.493 | -0.493 | 1.42 | 0.4413 | 0.5955 | 1.00 | 5.86 | 819,127.70 | -20.68 | -30.65 | -25.76 | -36.55 | 89.62 | 88.94 | -34.73 | -86.10 | 2.61 | -1.36 | 0.7482 | -- | 21.30 | 34.35 | 35.92 | -- | 3.36 | -- |
| SpringWorks Therapeutics Inc | 26.45m | -339.07m | 3.07bn | 305.00 | -- | 5.41 | -- | 116.12 | -5.15 | -5.15 | 0.4007 | 7.66 | 0.0432 | -- | -- | 86,731.15 | -55.31 | -36.97 | -60.58 | -39.49 | 93.86 | -- | -1,281.78 | -2,176.46 | 6.77 | -- | 0.00 | -- | -- | -- | -17.19 | -- | 90.68 | -- |
| Biohaven Ltd | 0.00 | -517.18m | 3.10bn | 239.00 | -- | 9.53 | -- | -- | -6.83 | -6.83 | 0.00 | 3.68 | 0.00 | -- | -- | 0.00 | -99.74 | -- | -123.66 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 28.43 | -- | -- | -- |
| Dyne Therapeutics Inc | 0.00 | -257.40m | 3.11bn | 143.00 | -- | 5.81 | -- | -- | -3.97 | -3.97 | 0.00 | 5.49 | 0.00 | -- | -- | 0.00 | -63.48 | -52.81 | -67.12 | -57.45 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -40.36 | -- | 40.32 | -- |
| Corcept Therapeutics Incorporated | 523.53m | 118.02m | 3.14bn | 352.00 | 28.22 | 5.73 | 26.39 | 6.00 | 1.07 | 1.07 | 4.74 | 5.27 | 0.822 | 1.12 | 11.13 | 1,487,298.00 | 18.53 | 21.17 | 21.50 | 23.85 | 98.54 | 98.52 | 22.54 | 27.23 | 5.10 | -- | 0.00 | 0.00 | 20.04 | 13.93 | 4.66 | 7.08 | -14.15 | -- |
| Guardant Health Inc | 603.73m | -460.90m | 3.32bn | 1.78k | -- | 48.33 | -- | 5.49 | -3.92 | -3.92 | 5.17 | 0.5607 | 0.3754 | 4.37 | 7.03 | 339,362.00 | -28.66 | -22.26 | -33.02 | -24.59 | 60.37 | 64.62 | -76.34 | -97.07 | 5.66 | -59.55 | 0.9435 | -- | 25.45 | 44.14 | 26.76 | -- | 0.2786 | -- |
| Ultragenyx Pharmaceutical Inc | 442.59m | -613.35m | 3.34bn | 1.28k | -- | 23.78 | -- | 7.54 | -8.02 | -8.02 | 5.75 | 1.69 | 0.329 | 1.61 | 6.18 | 346,854.20 | -45.59 | -33.35 | -55.09 | -38.30 | 88.59 | 93.13 | -138.58 | -154.71 | 2.28 | -- | 0.00 | -- | 19.52 | 53.18 | 14.25 | -- | 62.91 | -- |
| Axsome Therapeutics Inc | 251.02m | -296.38m | 3.49bn | 545.00 | -- | 24.20 | -- | 13.89 | -6.38 | -6.38 | 5.41 | 3.03 | 0.537 | 2.11 | 3.43 | 460,592.70 | -63.40 | -64.55 | -85.88 | -82.23 | 90.12 | -- | -118.07 | -227.05 | 3.09 | -55.54 | 0.556 | -- | 440.80 | -- | -27.84 | -- | 77.86 | -- |
Data as of May 31 2024. Currency figures normalised to Corcept Therapeutics Inc's reporting currency: US Dollar USD
52.78%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 31 Mar 2024 | 14.10m | 13.62% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 9.33m | 9.01% |
| Ingalls & Snyder LLCas of 31 Mar 2024 | 8.30m | 8.02% |
| Renaissance Technologies LLCas of 31 Mar 2024 | 7.12m | 6.88% |
| Parallel Advisors LLCas of 31 Mar 2024 | 3.82m | 3.69% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 3.58m | 3.45% |
| Dimensional Fund Advisors LPas of 31 Mar 2024 | 2.57m | 2.48% |
| Geode Capital Management LLCas of 31 Mar 2024 | 2.16m | 2.08% |
| First Trust Advisors LPas of 31 Mar 2024 | 1.84m | 1.78% |
| Boston Trust Walden, Inc.as of 31 Mar 2024 | 1.84m | 1.77% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
